Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Merck's HIV pill met key efficacy and safety goals in Phase 3 trials, matching Biktarvy as the FDA reviews its application with a 2026 decision date.
The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck & Co. Inc. (NYSE:MRK) on Wednesday announced ...
Daniel O'Day, Chairman & CEO, stated that "our third quarter earnings underscore the growing momentum you're seeing from Gilead today, which is driven by our strong portfolio and the impressive ...
Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
B/F/TAF shows lower ART switching rates and higher persistence among HIV patients, especially those with mental health or substance use disorders. Medicare claims data analysis indicates B/F/TAF has ...
Zacks Investment Research on MSN
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline
Gilead Sciences, Inc.’s GILD posted 3% year-over-year growth in total revenues for the third quarter of 2025. Total revenues comprise product sales and royalty, contract and other revenues. While ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback